NYSEAMERICAN:LCTX Lineage Cell Therapeutics Q3 2026 Earnings Date & Estimates $1.00 -0.03 (-2.91%) Closing price 10/30/2026 04:10 PM EasternExtended Trading$1.01 +0.01 (+1.00%) As of 10/30/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lineage Cell Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Lineage Cell Therapeutics in Q3 2026Lineage Cell Therapeutics is expected to post earnings of -$0.02 per share on revenue of $2.32 million. In the same quarter a year earlier Lineage Cell Therapeutics reported -$0.13 per share on revenue of $3.68 million. Lineage Cell Therapeutics last reported on August 6, 2026, posting -$0.03 per share and missing the -$0.0283 consensus estimate. Lineage Cell Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.02Expected Revenue$2.32 millionPrior-Year EPS-$0.13Prior-Year Revenue$3.68 millionExpected Revenue Growth-37.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.03 (Missed by -$0.0017)Last Quarter Revenue$1.07 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Lineage Cell Therapeutics Q3 2026 Earnings FAQ When does Lineage Cell Therapeutics report Q3 2026 earnings? Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Lineage Cell Therapeutics' Q3 2026 earnings call? Lineage Cell Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Lineage Cell Therapeutics? Analysts expect Lineage Cell Therapeutics to post earnings of -$0.02 per share for Q3 2026. How much revenue is Lineage Cell Therapeutics expected to report? The consensus revenue estimate for Lineage Cell Therapeutics is $2.32 million for Q3 2026. Lineage Cell Therapeutics Earnings HeadlinesLineage Cell Therapeutics Provides Update On ReSonance Program For Hearing LossOctober 29 at 5:18 PM | marketscreener.comMLineage Provides Update on ReSonance® Program for Hearing LossOctober 29 at 12:14 PM | marketscreener.comMThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 31 at 1:00 AM | Porter & Company (Ad)Average analyst price target for Lineage Cell Therapeutics rises 13.67% to ₪1,962.32October 4, 2026 | msn.comLineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing PlatformSeptember 8, 2026 | markets.ft.comLineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical RiskSeptember 1, 2026 | seekingalpha.comSee More Lineage Cell Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lineage Cell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lineage Cell Therapeutics and other key companies, straight to your email. Email Address About Lineage Cell TherapeuticsLineage Cell Therapeutics (NYSEAMERICAN:LCTX) is a biotechnology company focused on developing allogeneic cell therapies for unmet medical needs. The company uses its proprietary cell differentiation and manufacturing technologies to create specialized human cells intended to replace, repair or support damaged tissues. Lineage’s lead program, OpRegen, is an investigational retinal pigment epithelium cell replacement therapy being developed for geographic atrophy, an advanced form of dry age-related macular degeneration. The company has also developed cell therapy programs targeting neurological and sensory conditions, including oligodendrocyte progenitor cells for spinal cord injury and auditory neuronal progenitor cells for hearing loss. Based in Carlsbad, California, Lineage conducts research and clinical development primarily in the United States and works with commercial and strategic partners to advance its programs. The company was formerly known as BioTime, Inc. and adopted the Lineage Cell Therapeutics name in 2019. Brian M. Culley serves as chief executive officer.View Lineage Cell Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Silicon Shock: Intel's 25% Valuation ResetMarketBeat Week in Review – 10/26 - 10/30DoorDash's $17 Billion Bet on Instacart Faces a Long Regulatory Road AheadAmazon's Record Margins Couldn't Stop the Sell-Off—Here's WhyStarbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?Breaching the Valuation: The Real Reason Fortinet Dropped Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
